132 related articles for article (PubMed ID: 37222390)
1. KRAS mutations upregulate Runx1 to promote occurrence of head and neck squamous cell carcinoma.
Deng M; Guo J; Ling Z; Zhang C; He L; Fan Z; Cheng B; Xia J
Mol Carcinog; 2023 Sep; 62(9):1284-1294. PubMed ID: 37222390
[TBL] [Abstract][Full Text] [Related]
2. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
[TBL] [Abstract][Full Text] [Related]
3. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H
BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
[TBL] [Abstract][Full Text] [Related]
5. Effect of actionable somatic mutations on racial/ethnic disparities in head and neck cancer prognosis.
Wu ES; Park JY; Zeitouni JA; Gomez CR; Reis IM; Zhao W; Kwon D; Lee E; Nelson OL; Lin HY; Franzmann EJ; Savell J; McCaffrey TV; Goodwin WJ; Hu JJ
Head Neck; 2016 Aug; 38(8):1234-41. PubMed ID: 27028310
[TBL] [Abstract][Full Text] [Related]
6. SUZ12 is a novel putative oncogene promoting tumorigenesis in head and neck squamous cell carcinoma.
Wu Y; Hu H; Zhang W; Li Z; Diao P; Wang D; Zhang W; Wang Y; Yang J; Cheng J
J Cell Mol Med; 2018 Jul; 22(7):3582-3594. PubMed ID: 29667751
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
8.
Mustansar T; Mirza T; Hussain M
Biotech Histochem; 2023 Nov; 98(6):382-390. PubMed ID: 37013448
[TBL] [Abstract][Full Text] [Related]
9. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
10. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
12. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Hah JH; Zhao M; Pickering CR; Frederick MJ; Andrews GA; Jasser SA; Fooshee DR; Milas ZL; Galer C; Sano D; William WN; Kim E; Heymach J; Byers LA; Papadimitrakopoulou V; Myers JN
Head Neck; 2014 Nov; 36(11):1547-54. PubMed ID: 24123531
[TBL] [Abstract][Full Text] [Related]
13. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
15. Molecular and IHC analysis of head and neck carcinomas associated with HPV infection.
Stanek L; Glendova K; Tesarova P; Gurlich R; Holeckova P; Musil Z; Hrudka J; Pala M; Mateicka F; Chovanec M
Bratisl Lek Listy; 2019; 120(11):832-838. PubMed ID: 31747763
[TBL] [Abstract][Full Text] [Related]
16. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
[TBL] [Abstract][Full Text] [Related]
17. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Jagadeeshan S; Suryamohan K; Shin N; Mathukkada S; Boyko A; Melikhova D; Tsareva A; Yunusova L; Pravdivtseva E; Stupichev D; Shaposhnikov K; Peterson A; Bednyagin L; Shugaev-Mendosa E; Kessler L; Burrows F; Ho AL; Agrawal N; Pearson AT; Izumchenko E; Cole G; Elkabets M; Rosenberg AJ
Oral Oncol; 2024 Feb; 149():106688. PubMed ID: 38219706
[TBL] [Abstract][Full Text] [Related]
18.
GarcĂa-Carracedo D; Cai Y; Qiu W; Saeki K; Friedman RA; Lee A; Li Y; Goldberg EM; Stratikopoulos EE; Parsons R; Lu C; Efstratiadis A; Philipone EM; Yoon AJ; Su GH
Mol Cancer Res; 2020 Jun; 18(6):822-834. PubMed ID: 32152233
[TBL] [Abstract][Full Text] [Related]
19. CEACAM5 inhibits the lymphatic metastasis of head and neck squamous cell carcinoma by regulating epithelial-mesenchymal transition via inhibiting MDM2.
Wang X; Li Y; Pan M; Lu T; Wang M; Wang Z; Liu C; Hu G
Clin Sci (Lond); 2022 Nov; 136(22):1691-1710. PubMed ID: 36377775
[TBL] [Abstract][Full Text] [Related]
20. Tipifarnib in Head and Neck Squamous Cell Carcinoma With
Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn MJ; Boni V; Even C; Fayette J; Flor MJ; Harrington K; Kim SB; Licitra L; Nixon I; Saba NF; Hackenberg S; Specenier P; Worden F; Balsara B; Leoni M; Martell B; Scholz C; Gualberto A
J Clin Oncol; 2021 Jun; 39(17):1856-1864. PubMed ID: 33750196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]